本文關(guān)鍵詞： 膠質(zhì)瘤 MicroRNA 轉(zhuǎn)移性 侵襲性 MMP-16　出處：《蘇州大學(xué)》2016年博士論文　論文類型：學(xué)位論文

【摘要】：背景和目的神經(jīng)膠質(zhì)瘤是最常見的原發(fā)性惡性腦腫瘤,具有惡性增值、血管生成和侵襲周圍正常腦組織的特征。盡管經(jīng)過積極的手術(shù)、放療和化療治療,膠母細(xì)胞瘤患者的中位存活期僅僅有12-15個月。腫瘤侵襲是腫瘤治療失敗的主要原因。為延長患者生存期,提高患者生存質(zhì)量,迫切需要新的臨床生物標(biāo)記和治療靶點(diǎn),從而提出抑制或減少腫瘤細(xì)胞侵襲能力的新治療方案。MicroRNAs(miRNAs)是一類參與調(diào)控不同生物過程的異常非編碼RNA(長度大約為22個核苷酸)。通過使用實(shí)時定量PCR發(fā)現(xiàn)microRNA-132(mi R-132)在膠質(zhì)瘤組織中顯著異常表達(dá)�；趍iR-132靶基因的假設(shè),我們預(yù)測miR-132和基質(zhì)金屬蛋白酶(MMP)家族中的一種蛋白MMP-16(MT-MP3)有著顯著關(guān)聯(lián)。在人源膠質(zhì)瘤細(xì)胞株A172,SHG44和U87中過表達(dá)miR-132可以抑制細(xì)胞侵襲和轉(zhuǎn)移。而且在A172,SHG44和U87細(xì)胞中通過使miR-132的過表達(dá)從而減少了MMP-16的表達(dá)。總結(jié)以上結(jié)果分析:miR-132通過MMP-16影響膠質(zhì)瘤細(xì)胞侵襲和轉(zhuǎn)移,并且在膠質(zhì)瘤中miR-132作為一類抑制轉(zhuǎn)移相關(guān)基因的miRNA而存在。MicroRNAs(mi RNAs)是較短的單鏈核苷酸RNA分子,通過結(jié)合它們靶基因的mRNA分子的3'非編碼區(qū)來調(diào)控基因表達(dá),從而抑制基因轉(zhuǎn)錄或誘導(dǎo)mRNA降解。miRNAs控制細(xì)胞生長、增殖、新陳代謝和凋亡。事實(shí)上,特殊類型的miRNA失調(diào)已經(jīng)被證明與特定類型的腫瘤相關(guān)聯(lián)。例如,miR-16在膠質(zhì)瘤細(xì)胞低表達(dá)并且抑制Bcl-2表達(dá);在轉(zhuǎn)移性膠質(zhì)瘤細(xì)胞中miR-145過表達(dá),并且抑制ADAM17表達(dá)�；|(zhì)金屬蛋白酶16(Matrix metalloprotease 16)是一類膜型金屬蛋白酶。作為酶原,通過激活proMMP-2(明膠酶A)活性來起作用。MMP-16是由細(xì)胞分泌產(chǎn)生。然而,酶譜顯示明膠酶激活活化的MMP-2是激活MMP-16的間接機(jī)制。MMP-2可以裂開基底膜上的膠原蛋白IV,參與腫瘤轉(zhuǎn)移過程。毫無疑問,在胃癌、肝細(xì)胞癌、前列腺癌和黑色素細(xì)胞瘤中mmp-16的高表達(dá)與腫瘤細(xì)胞侵襲力增加相關(guān)聯(lián)。本研究不僅要探討mir-132在非瘤腦組織、不同級別的人腦膠質(zhì)瘤組織以及三個惡性膠質(zhì)瘤細(xì)胞系(a172,shg44和u87)中的表達(dá),而且進(jìn)一步通過體外試驗(yàn)探討mir-132與人腦膠質(zhì)瘤細(xì)胞侵襲性的相關(guān)性。本研究還旨在為未來進(jìn)一步深入研究mir-132在人類神經(jīng)膠質(zhì)瘤中的作用機(jī)制奠定基礎(chǔ)。一、材料和方法1.通過使用microrna.orgdatabase、thedatabaseonpredicted和publishedmicrornas(mirwalk),我們預(yù)測mirna-132(mir-132)與惡性腦腫瘤具有較強(qiáng)關(guān)聯(lián)性。2.化學(xué)合成的mir-132寡核苷酸隨機(jī)序列通過脂質(zhì)體2000被轉(zhuǎn)染進(jìn)惡性膠質(zhì)瘤細(xì)胞株a172,shg44和u87中。3.人源膠質(zhì)瘤細(xì)胞株a172,shg44和u87的轉(zhuǎn)染效率通過流式細(xì)胞術(shù)和綠色熒光檢測。4.使用實(shí)時定量pcr(qrt-pcr)分別檢測非瘤腦組織和人類膠質(zhì)瘤組織標(biāo)本中mir-132表達(dá)情況。5.使用transwell實(shí)驗(yàn)檢測mir-132對人源膠質(zhì)瘤細(xì)胞株a172,shg44和u87中的侵襲能力的影響。6.使用westernblot檢測mmp-2和mmp-16表達(dá)情況。7.熒光素酶報(bào)告實(shí)驗(yàn)證明mmp-16是mir-132直接靶向基因。8.顯示的數(shù)據(jù)為均值±標(biāo)準(zhǔn)差。使用spss版本12.0windows版本軟件。使用方差分析(anova)和student'st-test進(jìn)行統(tǒng)計(jì)分析。經(jīng)過統(tǒng)計(jì)分析p值0.05。二、結(jié)果1.mir-132在膠質(zhì)瘤組織中的表達(dá)低于正常腦組織。本研究中使用實(shí)時定量pcr檢測mir-132在11例低級別膠質(zhì)瘤組織、12例高級別膠質(zhì)瘤組織和8例正常腦組織中的表達(dá)情況。其實(shí)驗(yàn)結(jié)果顯示:相對于正常腦組織,mir-132在膠質(zhì)瘤組織中的表達(dá)顯著降低;同時與正常腦組織相比,mir-132在膠質(zhì)瘤細(xì)胞株(a172,shg44和u87)中的表達(dá)更低。mir-132在膠質(zhì)瘤組織和膠質(zhì)瘤細(xì)胞株的下調(diào)表明mir-132也許是膠質(zhì)瘤治療的潛在靶點(diǎn)。2.mir-132抑制膠質(zhì)瘤細(xì)胞的侵襲能力。使用transwell實(shí)驗(yàn)檢測mir-132對人源膠質(zhì)瘤細(xì)胞株a172,shg44和u87中的侵襲能力的影響。本研究將mir-132模擬物和抑制劑被轉(zhuǎn)染進(jìn)人源膠質(zhì)瘤細(xì)胞a172、shg44和u87。mir-132模擬物或干擾rna轉(zhuǎn)染后的72小時,a172、shg44和u87被接種于上室,48小時后通過細(xì)胞外基質(zhì)侵入的細(xì)胞被拍片和計(jì)數(shù)。在所有的細(xì)胞株中,相對于對照組,mir-132減少了侵入細(xì)胞的數(shù)量。實(shí)驗(yàn)數(shù)據(jù)表明mir-132是體外實(shí)驗(yàn)中細(xì)胞侵襲和遷移的調(diào)控分子。3.mmp-16mrna在膠質(zhì)瘤組織的表達(dá)。實(shí)時熒光定量pcr分析表明:相對于8例正常腦組織,mmp-16mrna在11例低級別和12例高級別膠質(zhì)瘤組織的表達(dá)顯著增高。結(jié)果發(fā)現(xiàn):mir-132在膠質(zhì)瘤組織中的表達(dá)低于正常腦組織。由此說明在腫瘤組織中mmp-16mrna的表達(dá)量較mir-132表達(dá)高,表明在腫瘤組織中mmp-16mrna的表達(dá)與mir-132的表達(dá)呈負(fù)相關(guān)。4.mir-132下調(diào)mmp-16mrna的表達(dá)。為了進(jìn)一步闡明mir-132在膠質(zhì)瘤細(xì)胞中抑制細(xì)胞侵襲能力的機(jī)制,本研究使用targetscan5andmirbase預(yù)測mir-132的靶基因,這些軟件顯示:mmp-16可能作為mir-132直接靶向調(diào)節(jié)基因,在腫瘤的細(xì)胞轉(zhuǎn)移和侵襲中扮演重要角色。同時運(yùn)用rt-pcr實(shí)驗(yàn)和qrt-pcr實(shí)驗(yàn)檢測發(fā)現(xiàn):與對照組細(xì)胞相比,轉(zhuǎn)染了mir-132模擬物的膠質(zhì)瘤細(xì)胞(a172,shg44和u87)顯著降低了mmp-16mrna的表達(dá)水平。以上的結(jié)果表明:mmp-16可能作為mir-132直接靶向調(diào)節(jié)基因,從而抑制膠質(zhì)瘤細(xì)胞的遷移和侵襲能力。5.mir-132直接靶向調(diào)節(jié)mmp-16基因的表達(dá)。本研究運(yùn)用westernblot分別檢測在轉(zhuǎn)染mir-132后a172,shg44和u87中mmp-16蛋白的表達(dá)水平,其結(jié)果表明:mmp-16的蛋白表達(dá)水平在被轉(zhuǎn)染mir-132模擬物和抑制物后分別被下調(diào)和上調(diào)。進(jìn)一步通過熒光素酶實(shí)驗(yàn)檢測發(fā)現(xiàn):mir-132直接抑制了mmp-16基因mrna的3’-utr表達(dá),從而證實(shí)mmp-16是mir-132天然靶向調(diào)節(jié)基因。6.mmp-16作為mmp-2的活化劑激活mmp-2蛋白表達(dá)水平。mmp-16是一種膜結(jié)合型mmp,能激活mmp-2來增加侵襲能力。mmp-2被mmp-16激活,這是mmp-16功能的間接途徑。mir-132被預(yù)測靶向作用mmp-16(mt3-mmp,membranetype3mmp)(www.microrna.org)。westernblot和熒光素酶實(shí)驗(yàn)被用來驗(yàn)證這一假設(shè)。結(jié)果表明:miR-132通過調(diào)節(jié)MMP-16的表達(dá)從而影響MMP-2蛋白的表達(dá);miR-132的過度表達(dá)通過下調(diào)MMP-16的表達(dá),從而抑制人類膠質(zhì)瘤細(xì)胞(A172,SHG44和U87)的侵襲能力。三、結(jié)論Has-mi R-132基因是位于17號染色體(1953202-1953302),長為100bp的堿基對。在過去的幾年里,許多研究發(fā)現(xiàn)miR-132異常表達(dá)參與了不同腫瘤的發(fā)生、發(fā)展過程。例如:miR-132作為腫瘤抑制器在乳腺癌中抑制細(xì)胞增殖。而且,miR-132異常表達(dá)在原發(fā)性骨肉瘤,阿爾茲海默病、前列腺癌和胰腺癌中被發(fā)現(xiàn)。然而,mi R-132在膠質(zhì)瘤細(xì)胞遷移和侵襲中的作用仍有待探索。本研究發(fā)現(xiàn)miR-132的表達(dá)水平在膠質(zhì)瘤組織中低于正常腦組織,而且mi R-132抑制膠質(zhì)瘤細(xì)胞侵襲和遷移能力。被miR-132模擬物轉(zhuǎn)染的膠質(zhì)瘤細(xì)胞(A172,SHG44和U87)減少腫瘤細(xì)胞的遷移和侵襲能力,同時用miR-132抑制劑轉(zhuǎn)染上述細(xì)胞則產(chǎn)生相反的結(jié)果。MMP-16是一種膜結(jié)合型MMP,能激活MMP-2來增加侵襲能力。MMP-2被MMP-16激活,這是MMP-16功能的間接途徑。目前的研究結(jié)果表明了MMP-16與膠質(zhì)瘤細(xì)胞侵襲和遷移能力密切相關(guān)。以前的研究結(jié)果顯示減少的MMP-16的水平有效地抑制膠質(zhì)瘤細(xì)胞的侵襲性。MMP-16同時被發(fā)現(xiàn)擁有抗細(xì)胞外基質(zhì)組分的蛋白水解的活性,如III型膠原蛋白。在正常腦組織和星形膠質(zhì)瘤組織中,MT3-MMP可能參與了細(xì)胞外基質(zhì)更新。本研進(jìn)一步證實(shí)miR-132通過減少基質(zhì)金屬蛋白酶基因MMP-16的表達(dá)從而抑制膠質(zhì)瘤細(xì)胞(A172,SHG44和U87)侵襲和遷移能力�？偠灾�,本研究證實(shí):在惡性膠質(zhì)瘤細(xì)胞中,miR-132可能通過直接調(diào)節(jié)MMP-16蛋白的表達(dá)來影響膠質(zhì)瘤細(xì)胞的遷移和侵襲性中起重要作用;miR-132也許是膠質(zhì)瘤侵襲和轉(zhuǎn)移的潛在治療靶點(diǎn)。然而,在體內(nèi)試驗(yàn)中,MMP-16的活性是否通過miR-132被影響需要更進(jìn)一步的深入研究來確認(rèn)。
[Abstract]:Background and objective: glioma is the most common primary malignant brain tumors, with malignant proliferation, angiogenesis and invasion of surrounding normal brain tissue. Despite aggressive surgery, radiotherapy and chemotherapy in the treatment of patients with glioblastoma, the median survival is only 12-15 months. Tumor invasion is the main reason the failure of cancer treatment. To prolong the survival time of the patients, improve the quality of life of patients, urgent need for clinical biomarkers and new therapeutic targets, so as to put forward a new treatment scheme to suppress or reduce the invasiveness of.MicroRNAs (miRNAs) is a kind of different biological processes involved in the regulation of the abnormal RNA (encoding length is about 22 nucleotide). By using real-time quantitative PCR microRNA-132 (MI R-132) in glioma tissues significantly. Abnormal expression of miR-132 target genes based on the hypothesis, we predicted that miR-132 and matrix metalloproteinase The enzyme (MMP) a family of protein MMP-16 (MT-MP3) has a significant correlation. In human glioma cell lines A172, SHG44 and U87 over expression of miR-132 can inhibit the invasion and metastasis of cells. But in A172, SHG44 and U87 cells by overexpression of MMP-16 reduced the expression of miR-132. Summing up the above analysis results: miR-132 through the invasion and metastasis of MMP-16 glioma cells, and miR-132 as a kind of anti metastasis related gene miRNA in glioma and the presence of.MicroRNAs (MI RNAs) is a single nucleotide RNA molecular short, mRNA molecules through the combination of their target gene 3'encoding region of controlling gene the expression of proliferation, inhibit gene transcription or mRNA induced degradation of.MiRNAs in cell growth, apoptosis, and The new supersedes the old.. In fact, a special type of miRNA disorders has been proved with a specific type of tumor associated. For example, miR-16 Low expression in glioma cells and inhibit the expression of Bcl-2 in miR-145; metastasis of glioma cells by overexpression, and inhibit the expression of ADAM17. Matrix metalloproteinase 16 (Matrix metalloprotease 16) is a kind of membrane type metalloproteinase. As a zymogen, through the activation of proMMP-2 (gelatin A enzyme) activity is produced by.MMP-16 cell secretion. However, enzyme activation of gelatinase spectrum shows that the MMP-2 is.MMP-2 indirect mechanism activation of MMP-16 can cleave the basement membrane collagen IV in the metastatic process. There is no doubt that in gastric cancer, hepatocellular carcinoma, and the high expression of mmp-16 in tumor cells of prostate cancer and melanoma invasion is associated with increased the present study not only to explore mir-132 in non tumor brain tissues and glioma tissue of different levels and three malignant glioma cell lines (A172, SHG44 and U87) in the form of, and further By in vitro test on the invasion of the relationship between mir-132 and human glioma cells. This study also aims to lay the foundation for the future further research on the mechanism of mir-132 in human gliomas. Materials and methods, 1. by using microrna.orgdatabase, thedatabaseonpredicted and publishedmicrornas (mirwalk), mirna-132 (mir-132) and we predict malignant brain tumors has the strong association of.2. chemical synthesis of mir-132 by Lipofectamine 2000 random oligonucleotide sequences were transfected into glioma cell line A172,.3. human glioma cell line A172 source SHG44 and U87, SHG44 and U87 transfection efficiency by flow cytometry and green fluorescence detection of.4. using real-time quantitative PCR (qRT-PCR) were detected respectively. Non tumor brain tissue and mir-132 in human glioma tissues the expression of.5. using Transwell assay on human mir-132 glue Glioma cell lines A172, SHG44 and U87 in the invasion effect of.6. using Westernblot to detect MMP-2 and mmp-16 expression of.7. luciferase reporter experiments prove that mmp-16 is the direct target gene.8. to display mir-132 data as mean standard deviation. Use the SPSS version of the 12.0windows version of the software. Using analysis of variance (ANOVA) and student'st-test statistics through statistical analysis analysis. The p value of 0.05. two, the expression of 1.mir-132 in glioma tissues than in normal brain tissues. Mir-132 was detected in 11 cases of low grade glioma tissues using real-time quantitative PCR in this study, the expression of 12 cases of high grade glioma tissues and 8 cases of normal brain tissues. The experimental results show that compared to the normal brain tissue, the expression of mir-132 in glioma tissues was significantly decreased; compared with normal brain tissue, mir-132 in glioma cell lines (A172, SHG44 and U87) in the table .mir-132 was lower in down regulated glioma tissues and glioma cell lines revealed that mir-132 may be a potential target for the treatment of glioma.2.mir-132 inhibits glioma cells invasion. On human glioma cell line A172 using Transwell assay, mir-132, SHG44 and U87 in the effect of invasion. This study analogue of mir-132 and inhibitor were transfected into human glioma cell line A172, SHG44 and u87.mir-132 mimic or interfere with RNA 72 hours after transfection, A172, SHG44 and U87 were seeded in the upper chamber, 48 hours after the invasion through the extracellular matrix cells were filming and counting. In all of the cell lines, compared with the control group, mir-132 reduce the number of invasive cells. The experimental data show that mir-132 is the expression and regulation of molecular.3.mmp-16mrna invasion and migration of cells in vitro in glioma tissue. Real time fluorescence quantitative PCR analysis showed that: In 8 cases of normal brain tissue, the expression of mmp-16mrna in 11 cases of low grade and 12 cases of high grade glioma tissues increased significantly. The results showed that the expression of mir-132 in glioma tissues was lower than that in normal tissues. The expression of mmp-16mrna in tumor tissues with high expression of mir-132, expression of mir-132 and mmp-16mrna showed that the expression of in tumor tissues was negatively correlated with the down-regulation of.4.mir-132 mmp-16mrna. In order to further elucidate the mechanism of mir-132 inhibition of cell invasion in glioma cells, this study used targetscan5andmirbase target gene prediction of mir-132, the software shows that the mmp-16 could be used to directly target the mir-132 regulatory gene, plays an important role in the invasion and metastasis of tumor cells at the same time. By using the RT-PCR test and qRT-PCR test showed that: compared with the control group transfected glioma cells, mir-132 mimics fine The cell (A172, SHG44 and U87) significantly reduced the expression level of mmp-16mrna. The above results showed that mmp-16 could be used to directly target the mir-132 regulating gene expression and inhibition of migration and invasion of.5.mir-132 glioma cells to target the direct regulation of mmp-16 gene. In this study the use of Westernblot A172 were detected in mir-132 after transfection, expression the level of mmp-16 protein and SHG44 in U87, the results showed that the expression of mmp-16 in transfected mir-132 mimics and inhibitor respectively is downregulated and upregulated. Further by luciferase reporter assay found that mir-132 directly inhibits mmp-16 gene mRNA 3 -utr expression, thus confirming that mmp-16 is mir-132 natural targeting gene regulation.6.mmp-16 as an activator of MMP-2 activated MMP-2 Protein expression level of.Mmp-16 is a membrane-bound MMP, can activate MMP-2 to increase the invasion ability of.Mmp-2 was mmp-16 This is the.Mir-132 activation, mmp-16 function is predicted indirectly targeting mmp-16 (mt3-mmp, membranetype3mmp) (www.microrna.org).Westernblot and luciferase assays were used to test this hypothesis. The results show that miR-132 can affect the expression of MMP-2 protein by regulating the expression of MMP-16; overexpression of miR-132 by down regulating the expression of MMP-16, thus inhibiting human glioma cells (A172, SHG44 and U87) invasion. Three. Conclusion Has-mi R-132 gene is located on chromosome 17 (1953202-1953302), 100bp long base pairs. In the past few years, many studies have found that the abnormal expression of miR-132 in different tumors, such as tumor development process. Suppressor miR-132 cell proliferation inhibition in breast cancer. Moreover, the abnormal expression of miR-132 in primary osteosarcoma, Alzheimer's disease, prostate cancer and pancreatic cancer were found in natural. However, the role of MI R-132 in the invasion and migration of glioma cells remains to be explored. This study found that the expression level of miR-132 is lower than that of normal brain tissue in glioma tissues, and MI R-132 inhibited the invasion and migration of glioma cells. MiR-132 mimics transfected glioma cells (A172, SHG44 and U87) to reduce the migration and invasion of tumor cells, and the cells were transfected with miR-132 inhibitor nterproductive.MMP-16 is a membrane-bound MMP, can activate MMP-2 to increase the invasion ability of.MMP-2 activated by MMP-16, which is indirectly the function of MMP-16. The results indicated that the MMP-16 and the invasion and migration of glioma cells closely related. Previous studies showed decreased levels of MMP-16 inhibit glioma cell invasion of.MMP-16 was also found to have anti extracellular matrix components of protein water Solution of the activity, such as type III collagen. In normal brain tissues and glioma tissues, MT3-MMP may be involved in extracellular matrix update. This study further confirmed that miR-132 can inhibit glioma cells by decreasing the expression of matrix metalloproteinase gene MMP-16 (A172, SHG44 and U87) invasion and migration. In a word, this study confirmed: in malignant glioma cells, miR-132 may directly regulate the expression of MMP-16 protein by the effect plays an important role in migration and invasion of glioma cells; miR-132 may be a potential therapeutic target in the invasion and metastasis of glioma. However, in vivo experiment, the activity of MMP-16 through miR-132 is affected further further studies to confirm.

【學(xué)位授予單位】：蘇州大學(xué)
【學(xué)位級別】：博士
【學(xué)位授予年份】：2016
【分類號】：R739.41

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 徐俊杰;于洪泉;國巍;趙偉;金宏;溫娜;齊玲;;西蘭花多肽對大鼠C6膠質(zhì)瘤細(xì)胞生長的影響[J];中風(fēng)與神經(jīng)疾病雜志;2012年11期

2 徐俊杰;于洪泉;趙偉;金宏;溫娜;齊玲;劉興吉;;西蘭花多肽對C6膠質(zhì)瘤細(xì)胞的誘導(dǎo)凋亡作用[J];吉林大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2013年01期

3 仝海波,江澄川,唐鎮(zhèn)生,金一尊;膠質(zhì)瘤細(xì)胞化學(xué)增敏作用實(shí)驗(yàn)研究[J];山西臨床醫(yī)藥;2000年07期

4 李嗍,王楓,繆珊,駱文靜;過量鋅對鼠膠質(zhì)瘤細(xì)胞體外生長的影響[J];解放軍預(yù)防醫(yī)學(xué)雜志;2001年04期

5 梁一鳴,郭國慶,鄭少俊,沈偉哉;膠質(zhì)瘤血管內(nèi)皮生長因子表達(dá)的調(diào)節(jié)[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2001年02期

6 曲元明,韓韜,李桂林,王成偉;血管內(nèi)皮細(xì)胞生長因子抗體對膠質(zhì)瘤生長的影響[J];山東醫(yī)科大學(xué)學(xué)報(bào);2001年02期

7 黃強(qiáng),董軍;膠質(zhì)瘤的分子外科治療[J];中國微侵襲神經(jīng)外科雜志;2001年04期

8 葉明,周岱,周幽心,王瑋,傅建新,黃煜倫;血管內(nèi)皮生長因子在膠質(zhì)瘤中的表達(dá)[J];腫瘤;2002年06期

9 顧宇翔,陳銜城,王宇倩;膠質(zhì)瘤對親細(xì)胞非均質(zhì)分子脂質(zhì)和幾種藥物敏感性的比較[J];復(fù)旦學(xué)報(bào)(醫(yī)學(xué)版);2003年02期

10 王成偉 ,劉福生 ,曲元明 ,李桂林;血管內(nèi)皮生長因子抗體抑制膠質(zhì)瘤生長的實(shí)驗(yàn)研究[J];中華神經(jīng)外科雜志;2003年01期

相關(guān)會議論文 前10條

1 李飛;李梅;盧佳友;朱剛;林江凱;孟輝;吳南;陳志;馮華;;脂質(zhì)微區(qū)干擾劑甲基-β-環(huán)糊精影響C6膠質(zhì)瘤細(xì)胞侵襲和遷移的體外實(shí)驗(yàn)研究[A];中國醫(yī)師協(xié)會神經(jīng)外科醫(yī)師分會第四屆全國代表大會論文匯編[C];2009年

2 吳安華;王運(yùn)杰;Ohlfest JR;Wei Chen;Low WC;;膠質(zhì)瘤的生物治療-從實(shí)驗(yàn)室到臨床[A];中華醫(yī)學(xué)會神經(jīng)外科學(xué)分會第九次學(xué)術(shù)會議論文匯編[C];2010年

3 徐宏;韓楊云;孫中書;李新軍;;與膠質(zhì)瘤代謝通路相關(guān)的候選基因篩選[A];中華醫(yī)學(xué)會神經(jīng)外科學(xué)分會第九次學(xué)術(shù)會議論文匯編[C];2010年

4 潘冬生;;多基因修飾膠質(zhì)瘤細(xì)胞疫苗的抗腫瘤免疫反應(yīng)[A];中國醫(yī)師協(xié)會神經(jīng)外科醫(yī)師分會第六屆全國代表大會論文匯編[C];2011年

5 俞文華;車志豪;張祖勇;許培源;陸鏞民;傅林;朱強(qiáng);陳鋒;杜權(quán);;骨橋蛋白在膠質(zhì)瘤細(xì)胞中的表達(dá)及其信號傳導(dǎo)途徑[A];2005年浙江省神經(jīng)外科學(xué)術(shù)會議論文匯編[C];2005年

6 張震;徐克;;低強(qiáng)度超聲誘導(dǎo)C6膠質(zhì)瘤細(xì)胞凋亡的體外實(shí)驗(yàn)研究[A];中華醫(yī)學(xué)會第十三次全國超聲醫(yī)學(xué)學(xué)術(shù)會議論文匯編[C];2013年

7 蔣偉峰;高方友;尹浩;;白細(xì)胞介素-17及其受體在膠質(zhì)瘤中的表達(dá)及臨床意義[A];2013年貴州省神經(jīng)外科年會論文集[C];2013年

8 徐慶生;張小兵;周永慶;;膠質(zhì)瘤干細(xì)胞及其放療敏感性[A];2011年浙江省神經(jīng)外科學(xué)學(xué)術(shù)年會論文匯編[C];2011年

9 楊孔賓;趙世光;劉炳學(xué);陳曉豐;戴欽舜;;K~+通道阻斷劑四乙胺對大鼠膠質(zhì)瘤細(xì)胞的增殖和凋亡影響[A];中國醫(yī)師協(xié)會神經(jīng)外科醫(yī)師分會第四屆全國代表大會論文匯編[C];2009年

10 黃強(qiáng);;膠質(zhì)瘤生成細(xì)胞研究[A];第三屆中國腫瘤學(xué)術(shù)大會教育論文集[C];2004年

相關(guān)重要報(bào)紙文章 前5條

1 衣曉峰　馮宇曦;中藥三氧化二砷有望成為治療膠質(zhì)瘤新藥[N];中國醫(yī)藥報(bào);2011年

2 記者 匡遠(yuǎn)深;讓膠質(zhì)瘤干細(xì)胞不再“繁殖”[N];健康報(bào);2011年

3 張獻(xiàn)懷　張文;瘤區(qū)埋雷 持續(xù)殺傷[N];健康報(bào);2007年

4 白毅;人腦膠質(zhì)瘤基礎(chǔ)與應(yīng)用研究喜結(jié)“九大碩果”[N];中國醫(yī)藥報(bào);2006年

5 王德江；劉藏；王貴懷；曹勇；王新生；肖新如;交流最新進(jìn)展 提高診治水平[N];中國醫(yī)藥報(bào);2005年

相關(guān)博士學(xué)位論文 前10條

1 董軍;CUL4B在神經(jīng)膠質(zhì)細(xì)胞瘤中的作用研究[D];山東大學(xué);2015年

2 張睿;循環(huán)miR-221/222在膠質(zhì)瘤診斷與預(yù)后中的價值與基于CED的中樞神經(jīng)系統(tǒng)給藥新方法的研究[D];山東大學(xué);2015年

3 許森林;ALDH1A1在膠質(zhì)瘤侵襲和結(jié)直腸癌轉(zhuǎn)移中的作用和機(jī)制[D];第三軍醫(yī)大學(xué);2015年

4 王嘯;靶向嵌段共聚物膠束在膠質(zhì)瘤磁共振成像、藥物輸送及治療的應(yīng)用[D];安徽醫(yī)科大學(xué);2015年

5 廖紅展;鋅指轉(zhuǎn)錄因子SNAI2在miR-203的影響下通過上皮間質(zhì)轉(zhuǎn)化參與膠質(zhì)瘤耐藥機(jī)制的調(diào)節(jié)[D];南方醫(yī)科大學(xué);2015年

6 潘俊;IRG1促進(jìn)膠質(zhì)瘤增殖的作用機(jī)制及臨床意義[D];南方醫(yī)科大學(xué);2015年

7 鄭傳宜;膠質(zhì)瘤中GLUT3基因異常表達(dá)的意義及其相關(guān)調(diào)控機(jī)制[D];南方醫(yī)科大學(xué);2015年

8 徐紅超;氬氦冷凍消融聯(lián)合GM-CSF治療膠質(zhì)瘤小鼠的療效及其對小鼠脾臟樹突狀細(xì)胞免疫功能影響[D];南方醫(yī)科大學(xué);2015年

9 黃素寧;TNFRSF6B在膠質(zhì)瘤中的表達(dá)及對膠質(zhì)瘤細(xì)胞增殖及凋亡的作用研究[D];南方醫(yī)科大學(xué);2015年

10 熊偉;GBE1在人腦膠質(zhì)細(xì)胞瘤中的表達(dá)及干預(yù)實(shí)驗(yàn)研究[D];第四軍醫(yī)大學(xué);2015年

相關(guān)碩士學(xué)位論文 前10條

1 張大慶;單核細(xì)胞趨化蛋白-1在骨髓間充質(zhì)干細(xì)胞向膠質(zhì)瘤細(xì)胞趨化中的作用研究[D];大連醫(yī)科大學(xué);2012年

2 黃俊龍;ADC值與膠質(zhì)瘤Ki-67、MGMT的相關(guān)性研究[D];福建醫(yī)科大學(xué);2015年

3 李明聰;下調(diào)Pygo2對U251及U251起源的膠質(zhì)瘤干細(xì)胞生物學(xué)特性的影響[D];福建醫(yī)科大學(xué);2015年

4 徐云峰;膠質(zhì)瘤干細(xì)胞的3D培養(yǎng)及其核酸適體篩選的探索[D];福建醫(yī)科大學(xué);2015年

5 張靜文;T細(xì)胞過繼免疫治療小鼠腦膠質(zhì)瘤原位模型的研究[D];河北醫(yī)科大學(xué);2015年

6 洪宇;膠質(zhì)瘤瘤周水腫、病理級別、Ki-67表達(dá)三者相關(guān)性研究[D];石河子大學(xué);2015年

7 姬云翔;磷酸化Cx43蛋白在人膠質(zhì)瘤細(xì)胞中表達(dá)及其與腫瘤細(xì)胞增殖相關(guān)性研究[D];石河子大學(xué);2015年

8 朱峰;OPN的異常表達(dá)與膠質(zhì)瘤的相關(guān)性研究[D];河北醫(yī)科大學(xué);2015年

9 劉兵;SENP1表達(dá)水平對人腦膠質(zhì)瘤發(fā)生發(fā)展的作用機(jī)制及其相關(guān)性[D];河北醫(yī)科大學(xué);2015年

10 李文華;Slit2/Robo1在人腦膠質(zhì)瘤中的表達(dá)及臨床意義[D];河北醫(yī)科大學(xué);2015年

，

本文編號：1477168